The rapid evolution of vaccine technologies has fundamentally transformed the landscape of preventive and therapeutic medicine, particularly with the emergence of nucleic acid-based vaccines such as DNA and RNA platforms. This study provides a comprehensive theoretical and analytical exploration of advancements in vaccine development, focusing on DNA vaccines, mRNA-based systems, and innovative delivery technologies including electroporation, microneedles, intranasal systems, and nanoparticle-based carriers. Drawing exclusively from the provided references, the research examines immunological mechanisms, delivery challenges, adjuvant innovations, and translational potential in infectious diseases and cancer therapy.

In recent years, the convergence of molecular biology, immunology, and nanotechnology has enabled the development of highly sophisticated vaccine platforms capable of addressing complex and rapidly evolving pathogens. Unlike traditional vaccines, nucleic acid-based approaches rely on the host’s cellular machinery to produce antigenic proteins, thereby mimicking natural infection processes and eliciting robust immune responses. This intrinsic mechanism not only enhances the precision of immune targeting but also reduces the risks associated with live or attenuated pathogens. Furthermore, these platforms offer remarkable flexibility, allowing rapid redesign and deployment in response to emerging infectious threats, which has been particularly evident during global health emergencies.

The study highlights the role of lipid nanoparticles, chitosan-based systems, and cell-penetrating peptides in enhancing vaccine efficacy. These delivery systems are critical in protecting fragile nucleic acid molecules from enzymatic degradation, improving cellular uptake, and ensuring efficient antigen expression. Additionally, they contribute to controlled release mechanisms and targeted delivery, which are essential for optimizing immune responses. The integration of such advanced carriers has significantly improved the clinical viability of nucleic acid vaccines, bridging the gap between laboratory research and real-world application.

Additionally, it evaluates emerging approaches such as plant-based vaccines, virus-like particles, and mucosal immunization strategies. These novel platforms represent a shift toward more sustainable, scalable, and patient-friendly vaccination methods. For instance, plant-based vaccines offer cost-effective production and reduced dependency on complex manufacturing infrastructure, while virus-like particles provide strong immunogenicity without the risks associated with infectious agents. Mucosal immunization, particularly via intranasal delivery, is gaining increasing attention for its ability to induce both systemic and localized immune responses.

DNA vaccines, mRNA vaccines, vaccine delivery systems, electroporation, nanotechnology, immunogenicity, mucosal immunity

Schmidt, G., Gadermaier, G., Pertl, H., Siegert, M., Oksman-Caldentey, K.M., Ritala, A., et al. (2008). Production of recombinant allergens in plants. Phytochemical Reviews, 7, 539–552.

Walmsley, A.M., Arntzen, C.J. (2000). Plants for delivery of edible vaccines. Current Opinion in Biotechnology, 11, 126–129.

Rice, J., Ottensmeier, C.H., Stevenson, F.K. (2008). DNA vaccines: Precision tools for activating effective immunity against cancer. Nature Reviews Cancer, 8, 108–120.

Pokorna, D., Rubio, I., Müller, M. (2008). DNA vaccination via tattooing induces stronger immune responses. Genetic Vaccines and Therapy, 6, 4.

McAllister, J., Proll, D. (2004). Comparison of DNA vaccine delivery systems.

Bolhassani, A., Safaiyan, S., Rafati, S. (2011). Improvement of vaccine delivery systems for cancer therapy. Molecular Cancer, 10, 3.

Pires, A., Fortuna, A., Alves, G., Falcão, A. (2009). Intranasal drug delivery: How, why and what for? Journal of Pharmacy and Pharmaceutical Sciences, 12, 288–311.

Sullivan, S.P., Koutsonanos, D.G., Del Pilar Martin, M., et al. (2010). Dissolving polymer microneedle patches for influenza vaccination. Nature Medicine, 16, 915–920.

Lambricht, L., Lopes, A., Kos, S., et al. (2016). Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opinion on Drug Delivery, 13, 295–310.

Pagliari, S., Dema, B., Sanchez-Martinez, A., et al. (2023). DNA vaccines: History, molecular mechanisms and future perspectives. Journal of Molecular Biology, 435, 168297.

Gary, E.N., Weiner, D.B. (2020). DNA vaccines: Prime time is now. Current Opinion in Immunology, 65, 21–27.

Eusébio, D., Neves, A.R., Costa, D., et al. (2021). Methods to improve the immunogenicity of plasmid DNA vaccines. Drug Discovery Today, 26, 2575–2592.

Anderson, E.J., Rouphael, N.G., Widge, A.T., et al. (2020). Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine. New England Journal of Medicine, 383, 2427–2438.

Kim, H., et al. (2023). Optimization of storage conditions for lipid nanoparticle-formulated RNA vaccines. Journal of Controlled Release, 353, 241–253.

Pambudi, N.A., Sarifudin, A., Gandidi, I.M., Romadhon, R. (2022). Vaccine cold chain management. Energy Reports, 8, 955–972.

Fan, T., Zhang, M., Yang, J., et al. (2023). Therapeutic cancer vaccines: Advancements and prospects. Signal Transduction and Targeted Therapy, 8, 450.

Beg, S., Almalki, W.H., Khatoon, F., et al. (2021). Nanocomplexes in nucleic acid delivery. Drug Discovery Today, 26, 1891–1903.

Ward, B.J., Gobeil, P., Seguin, A., et al. (2021). Plant-derived virus-like particle vaccine for COVID-19. Nature Medicine, 27, 1071–1078.